Fusion of vesicles into target membranes during many types of regulated exocytosis requires both SNARE-complex proteins and fusogenic lipids, such as phosphatidic acid. Mitochondrial fusion is less well understood but distinct, as it is mediated instead by the protein Mitofusin (Mfn). Here, we identify an ancestral member of the phospholipase D (PLD) superfamily of lipid-modifying enzymes that is required for mitochondrial fusion. Mitochondrial PLD (MitoPLD) targets to the external face of mitochondria and promotes transmitochondrial membrane adherence in a Mfn-dependent manner by hydrolysing cardiolipin to generate phosphatidic acid. These findings reveal that although mitochondrial fusion and regulated exocytic fusion are mediated by distinct sets of protein machinery, the underlying processes are unexpectedly linked by the generation of a common fusogenic lipid. Moreover, our findings suggest a novel basis for the mitochondrial fragmentation observed during apoptosis.
Fusion of vesicles into target membranes during many types of regulated exocytosis requires both SNARE-complex proteins and fusogenic lipids, such as phosphatidic acid.
Mitochondrial fusion is less well understood but distinct, as it is mediated instead by the protein Mitofusin (Mfn). Here, we identify an ancestral member of the phospholipase D (PLD) superfamily of lipid-modifying enzymes that is required for mitochondrial fusion. Mitochondrial PLD (MitoPLD) targets to the external face of mitochondria and promotes transmitochondrial membrane adherence in a Mfn-dependent manner by hydrolysing cardiolipin to generate phosphatidic acid. These findings reveal that although mitochondrial fusion and regulated exocytic fusion are mediated by distinct sets of protein machinery, the underlying processes are unexpectedly linked by the generation of a common fusogenic lipid. Moreover, our findings suggest a novel basis for the mitochondrial fragmentation observed during apoptosis.
Parallel dimerization of vesicle-and target-SNARE coiled-coil proteins tethers exocytic vesicles to the plasma membrane and drives fusion of the opposing bilayer membranes 1 . Although the SNAREs suffice to mediate detectable levels of fusion in isolation 2 , increasing their efficiency to physiological levels during regulated exocytosis requires additional factors in many settings, including manipulation of the lipid environment through the production of acidic fusogenic lipids such as phosphatidic acid and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P 2 ) by the enzymes PLD 3, 4 and PtdIns(4,5)P 2 kinase 5 . In contrast, fusion of mitochondria depends on Mfn (also known as Fzo) [6] [7] [8] , which tethers opposing mitochondrial outer membranes together through antiparallel dimerization of a coiled-coil domain 9 . In addition, the GTPase domain of Mfn performs an unknown but vital action in the fusion process 8, 10 . The mechanism through which Mfn promotes fusion of the outer membrane is not well understood, nor have additional components of the mammalian fusion machinery required for this step been identified. Here, we describe the unexpected finding that generation of phosphatidic acid, a lipid shown to facilitate specialized SNARE-complex driven vesicular fusion events in yeast 11 and mammals 3, 4 , is a key component in Mfn-mediated mitochondrial fusion.
BLAST search of the human genome using the PLD catalytic-site HKD motif 12 uncovered several previously undescribed members of the PLD superfamily, including a widely expressed protein (see Supplementary Information, Fig. S1 ) denoted MitoPLD, which encoded a predicted mitochondrial localization sequence (MLS; Fig. 1a and see Supplementary Information, Fig. S1 ). Unlike the classic mammalian isoforms PLD1 and PLD2 that encode PX, PH and PtdIns(4,5)P 2 -binding protein domains that mediate localization, and two copies of the HKD motif that juxtapose to form the catalytic site 13 , MitoPLD encodes solely a single HKD half-catalytic site. Phylogenetic analysis revealed that MitoPLD is a divergent and ancestral family member most similar to bacterial cardiolipin synthase and to bacterial endonuclease Nuc, a PLD superfamily member that also encodes a single half-catalytic site and dimerizes to function (see Supplementary Information,  Fig. S1 ) 14 . Confocal microscopy analysis of MitoPLD expressed as a carboxy-terminal fusion protein with EGFP confirmed its localization to mitochondria (Fig. 1b) , and the MLS was found to be necessary and sufficient for localization (Fig. 1c, d ). Most nuclear-encoded proteins targeted to the mitochondria through an amino-terminal MLS enter into the matrix through the protein import apparatus Tom (translocase of the outer membrane), and while doing so, undergo processing that removes the MLS 15 . However, western blot analysis of overexpressed MitoPLD revealed full-length rather than processed protein (Fig. 1e) , suggesting that the MLS, which also scored as a potential transmembrane domain (see Supplementary Information, Fig. S1 ), may be retained and serve to anchor MitoPLD to the outer membrane surface, as is the case for Tom20 (ref. 15 ). This possibility was addressed using protease surface digestion of intact mitochondria ( Fig. 1f and see Supplementary Information, Fig. S2 ), which confirmed the topology. Split-Venus complementation ( Fig. 1g ; which tests potential protein-protein interactions by assaying for reassembly of amino-and carboxy-terminal fragments of Venus fluroescent protein appended to the candidate interacting proteins), and coimmunoprecipitation (see Supplementary Information, Fig. S2 ) confirmed that MitoPLD dimerizes in vivo (the abnormal mitochondrial morphology is discussed in Fig. 2 ). However, modelling of the resulting N-terminally tethered dimer on bacterial Nuc 14 and PLD 16 suggested that the lipidhydrolysing catalytic pocket should paradoxically be oriented away from the mitochondrial outer membrane surface (Fig. 1h) , raising the intriguing question of what function this presumed enzyme undertakes.
An answer was suggested by the phenotype observed with moderate overexpression of MitoPLD (as opposed to the lower level of expression shown in Fig. 1b) , which consisted of aggregation of the normally well-distributed tubular mitochondria (Fig. 2a, control) into a seemingly continuous giant peri-nuclear mitochondrion (Fig. 2a, MitoPLD) . Specificity of the phenotype and confirmation that MitoPLD is a bona fide enzyme was demonstrated by overexpressing a mutant allele, H156N, in which the key catalytic histidine had been converted to an . The transmembrane domain (magenta) was not contained within the region modelled. MitoPLD is shown oriented with respect to the outer (OM) and inner (IM) mitochondrial membranes. C, N; C-and Ntermini. H156 is the key catalytic-site residue.
asparagine, which in all PLD family members studied to date results in complete loss of catalytic activity 13 . In this case, the normal mitochondrial tubular morphology was again disrupted, but was replaced instead by a collection of non-contiguous mitochondrial fragments (Fig. 2a,  H156N ). As MitoPLD dimerizes, this construct should be an effective dominant-negative allele. To confirm the requirement of MitoPLD for normal mitochondrial morphology, cell lines stably expressing short hairpin RNA (shRNA) directed against MitoPLD were generated. The cell lines similarly exhibited mitochondrial fragmentation, and as a measure of specificity of the RNA interference (RNAi) targeting, mitochondrial fragmentation could be rescued by expression of an RNAiresistant MitoPLD cDNA (Fig. 2b) . Electron microscopy analysis (Fig. 2c) confirmed and extended these findings; rather than being a continuous mitochondrion, the mitochondria in cells overexpressing MitoPLD were actually aggregated into a compound structure that was not resolvable at the confocal microscopy level. Strikingly, a regular and uniform distance (5.9 ± 1.8 nm, n = 20) was observed separating the opposing outer membranes of distinct mitochondria. In contrast, non-uniform and much larger separating distances were observed in cells expressing dominant-negative MitoPLD H156N or MitoPLD RNAi. Cells stably expressing elevated levels of MitoPLD or MitoPLD H156N remained viable, proliferated normally, did not exhibit translocation of cytochrome c into the cytoplasm ( Fig. 3a) and maintained mitochondrial membrane potential (ΔΨ m ; Fig. 3b) ; hence, the respective altered mitochondrial morphologies did not seem to trigger or result from apoptosis or major alterations in cell homeostasis. Taken together, these altered morphologies suggested that MitoPLD may function in mitochondrial fusion. To address this, a mitochondrial fusion assay 17 was performed and we found that cells deficient in MitoPLD or expressing the MitoPLD H156N dominant-negative allele exhibit dramatically decreased levels of fusion (Fig. 3c ).
Current models for mitochondrial fusion propose that the process is initiated by a tethering step carried out by Mfn, which juxtaposes opposing mitochondrial outer membranes approximately 16 nm apart 9 . Electron microscopy findings confirmed the separating distance reported for Mfn1 (16.4 ± 2.4 nm, n = 20), suggesting that MitoPLD-mediated aggregation (Figs 2c and 4a) brings the opposing outer membrane leaflets closer together, which can be observed even at the resolution level of confocal microscopy ( Fig. 4b ). This observation suggested that MitoPLD may function downstream of Mfn-mediated tethering to perform a subsequent step in the fusion process. To investigate this possibility, the epistatic relationship between Mfn-mediated tethering and MitoPLD-mediated aggregation was examined. There are two mammalian isoforms of Mfn, Mfn1 and Mfn2. Cells lacking Mfn1 have reduced rates of fusion, whereas cells lacking both Mfn1 and Mfn2 exhibit no fusion; both types of cells are characterized by fragmented mitochondria (Fig. 4c ) 18, 19 . MitoPLD was transfected into these cell lines and conversion of the fragmented mitochondria into aggregated mitochondria was observed in the absence of Mfn1, but not in the absence of both Mfn1 and Mfn2 (Fig. 4c ). These findings demonstrate that MitoPLD-induced aggregation requires at least low levels of Mfn activity. Conversely, transfection of the C-terminal portion of Mfn1 (tether; amino acids 331-741), which suffices to mediate tethering 9 , into cells expressing the dominant-negative MitoPLD H156N allele or into MitoPLD RNAi cells, succeeded in generating mitochondria tethered at a distance generally similar to that observed after transfection of the tether into wild-type cells (Fig. 4d) , suggesting that Mfn tethering does not require MitoPLD activity. Furthermore, transfection of the Mfn1 tether into cells overexpressing wild-type MitoPLD resulted in a separating distance similar to that observed when MitoPLD alone was overexpressed (Fig. 4d) , suggesting that the MitoPLD aggregation phenomenon dominates over the Mfn-induced tethering action. It is not known whether MitoPLD action precedes, follows or affects the action of the Mfn GTPase domain. Taken together, these results suggest that MitoPLD functions downstream of Mfn-mediated tethering. We propose that MitoPLD functions in trans to modify the lipid surface of the opposing mitochondrial outer membrane and that this modification occurs at physiologically significant rates only if Mfn tethers the respective mitochondria in opposition for an adequate period of time. However, this model raises issues regarding the mechanism of MitoPLD action.
The MitoPLD protein sequence is most similar to the bacterial endonuclease Nuc and bacterial cardiolipin synthase (but not to eukaryotic cardiolipin synthase, which is a member of an unrelated gene family). Neither nuclease activity nor cardiolipin synthetic activities could be detected (see Supplementary Information, Fig. S3) ; however, using one-dimensional (Fig. 5a ) and two-dimensional (Fig. 5b) thin layer chromatography (TLC), an altered profile of mitochondrial lipids was observed after MitoPLD overexpression, consisting of a decrease in cardiolipin (19 ± 6% of control levels, n = 3) and an increase in phosphatidic acid (199 ± 58% of control levels, n = 3). Small decreases in phosphatidylethanolamine were sometimes noted and limited hydrolysis of other phopholipids cannot be excluded. No changes in the levels of cardiolipin or phosphatidic acid were noted in cells overexpressing the MitoPLD dominant-negative H156N allele or in MitoPLD RNAi cells (Fig. 5b and data not shown), demonstrating linkage of the altered profile to MitoPLD enzymatic activity. Cardiolipin levels were also examined in cells overexpressing Mfn1. No decrease in cardiolipin was observed, demonstrating that mitochondrial aggregation per se does not deplete cardiolipin and thus providing specificity for the decrease observed when MitoPLD was overexpressed. Finally, a direct demonstration of MitoPLD hydrolysis was achieved using purified recombinant protein (Fig. 5c ) in combination with liposomes containing labelled cardiolipin. In the experiment shown in Fig. 5d , wild-type MitoPLD hydrolysed 8.4% of the labelled cardiolipin to generate phosphatidic acid, whereas no phosphatidic acid generation was observed in the absence of input protein or in the presence of catalytically inactive MitoPLD H156N . From a biochemical perspective, the identification of MitoPLD as an enzyme that hydrolyses cardiolipin to generate phosphatidic acid is not unreasonable, given its similarity to a bacterial cardiolipin synthase, which mediates the same reaction in the reverse direction. Moreover, cardiolipin-hydrolysing activities have previously been demonstrated for a bacterial PLD 20 . From a mitochondrial perspective, however, this could be considered a surprising finding, as cardiolipin is found predominantly on the inner leaflet of the mitochondrial inner membrane, whereas we present evidence here that MitoPLD localizes to the outer leaflet of the outer membrane. The outer membrane does contain 10-20% of the total mitochondrial cardiolipin 21, 22 , most of which is in the outer leaflet 22 at inner membrane-outer membrane contact sites. Moreover, cardiolipin has been shown to translocate in a regulatable manner from the inner membrane to the outer membrane 21 , and as cardiolipin remodelling takes place on the mitochondrial exterior or in the endoplasmic reticulum 23 , most cardiolipin presumably transits through the outer membrane post-synthesis before returning to the mitochondrial interior. Thus, an overexpressed outer membrane cardiolipin-modifying enzyme should eventually be able to gain access to most of the mitochondrial cardiolipin. Our findings have two important implications: first, they suggest that mitochondrial fusion takes place in the regions overlying contact sites, which is an attractive idea but one for which support has not previously been generated; second, they suggest a novel mechanism to link the mitochondrial fragmentation observed during apoptosis to the apoptotic process. The rate of fusion is known to decrease during apoptosis 24 . We propose that this may ensue from a combination of sequestration by tBid (a caspase-8-cleaved Bid fragment that triggers mitochondrial fragmentation) and/or decreased cardiolipin availability subsequent to apoptosis-induced cardiolipin deacylation 25 or cytochrome c-mediated cardiolipin peroxidation 26 . This would lead to decreased MitoPLD production of phosphatidic acid and an ensuing decrease in the rate of fusion, which would cause fragmentation if the level of fission remained unchanged. An analogous mechanism exists in yeast, where cell-cycle arrest-triggered fragmentation is mediated by the ubiquitination and downregulation of Mfn (also known as Fzo1) 27 . Here, we show a requirement for MitoPLD-mediated generation of phosphatidic acid in mitochondrial fusion. Thus far, we have uncovered no other roles for MitoPLD in the fusion process. Coimmunopreciptation analysis did not reveal an interaction between MitoPLD and Mfn1 or Mfn2, and levels of Mfn 1 and 2 protein expression were not altered in cells overexpressing wild-type or MitoPLD H156N , or in MitoPLD RNAi cells (see Supplementary Information, Fig. S2, and data not shown) . The requirement for production of phosphatidic acid is reminiscent of the requirement for classic PLD-dependent generation of phosphatidic acid in SNARE-mediated fusion of secretory vesicles with the plasma membrane during many types of regulated exocytosis 3, 4 and during sporulation in yeast 11 . Taken together, these findings reveal a common requirement for a specific manipulation of the lipid environment despite the lack of conservation of the associated protein machinery and mechanism of action. The role of phosphatidic acid remains undetermined -it may facilitate fusion by generating negative curvature in the opposing bilayers, by recruiting or activating other key proteins or enzymes, or by being further converted to other fusogenic lipids (such as diacylglycerol). Interestingly, phosphatidic acid has been shown to recruit Spo20, the yeast homologue of the mammalian t-SNARE 25, to sites of vesicle fusion through direct interaction 28 , and to accelerate the rate of mammalian SNARE-driven vesicle fusion in vitro 29 .
Mutations in Mfn2 are the most frequent cause of Charcot-MarieTooth type 2A disease, an inherited peripheral neuropathy 30 . Although the physiological consequence of MitoPLD deficiency is presently unknown, some possibilities are suggested by the localization of the human MitoPLD gene to 17p11.2 in a region frequently duplicated in Charcot-Marie-Tooth 1A disease and deleted in Smith-Magenis syndrome 31 , the latter of which is characterized, in part, by a peripheral neuropathy thought to ensue from heteroinsufficiency of an unknown gene in the region.
METHODS
General reagents. Cell culture media, DMEM, Opti-MEM-I, and LipofectAMINE Plus were from Invitrogen (Carlsbad, CA). MitoTracker Deep Red 633 was purchased from Molecular Probes (Carlsbad, CA). All other reagents were of analytical grade unless otherwise specified.
DNA manipulation. An EST clone (GenBank accession number, BI562496; IMAGE consortium clone number, 5298498) was identified through the tBlastn search with an HKD motif against the human EST database. The coding sequence of MitoPLD was PCR-amplified from the IMAGE consortium clone using primers 5ʹ-CTAGCTCGAGACCATGGGACGGTTGAGTTGG-3ʹ and 5ʹ-CGGATCCCG GGTTTGGCTTTCGCTGGAG-3ʹ terminating with XhoI and XmaI restriction sites, respectively. The resulting PCR product was subcloned in-frame into the XhoI and XmaI sites of pEGFP-N1 (Clontech, Mountain View, CA). MitoPLD   H156N was generated using the QuickChange Site-directed Mutagenesis kit (Stratagene, La Jolla, CA) with primers 5ʹ-CCCAGGCTACATGAATCACAAGTTTGC-3ʹ and 5ʹ-GCAAACTTGTGATTCATGTAGCCTGGG-3ʹ (mutations are underlined). The sequences of all plasmids generated were confirmed by sequencing.
Cell culture and transfection. Cells were maintained in DMEM supplemented with 10% calf serum (Hyclone, Logan, UT). Mifepristone-inducible NIH3T3 stable cells expressing Flag-tagged MitoPLD were generated using the GeneSwitch system (Invitrogen) and MitoPLD was induced by treatment with 1 nM mifepristone (Invitrogen) for 16-24 h. For transfections, cells were grown on coverslips in 35-mm dishes (3-4 ± 10 5 cells per dish) and then switched into Opti-MEM I media before being transfected with 1 μg DNA per dish by using LipofectAMINE Plus. Two hours post-transfection, the media were replaced with fresh growth medium, and the cells incubated a further 20-24 h.
Western blotting. Mitochondrial lysates (20 Tg) were subjected to 12% SDS-PAGE and transferred to nitrocellulose membranes. The blots were probed with indicated primary antibodies, followed by secondary antibodies conjugated with Alexa 680 (Molecular Probes) or IRDye 800 (Rockland Immunochemicals, Gilbertsville, PA). Fluorescent signals were detected with an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NB). Antibodies used in this study are as follows: anticytochrome c (Pharmingen, San Diego, CA), anti-Flag (M2; Sigma, St Louis, MO), anti-Hsp60 (Stressgen, San Diego, CA), anti-Smac (R&D Systems, Minneapolis, MN), anti-VDAC (Calbiochem, San Diego, CA), anti-TOM20 (FL-145, Santa Cruz, Santa Cruz, CA), anti-Mfn1 (see Supplementary Information, Methods) , anti-Mfn2 (see Supplementary Information, Methods) and Alexa 488-or Alexa 647-conjugated secondary antibodies (Molecular Probes).
Quantitative real-time PCR. Total RNA was isolated from HeLa cells as indicated using an RNeasy Mini Kit (Qiagen, Valencia, CA) and reverse transcribed into single stranded cDNA using the 1st Strand cDNA Synthesis Kit for RT-PCR (AMV; Roche, Palo Alto, CA). Quantitative real-time PCR analysis was performed using the LightCycler system (Roche) and FastStart DNA Master SYBR Green I (Roche). Calculated concentrations of MitoPLD cDNA were normalized with respect to the expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for each sample. Primers used for real time PCR were: human GAPDH, 5ʹ-GAAGGTGAAGGTCGGAGTC-3ʹ (sense) and 5ʹ-GAAGATGGTGATGGGATTTC-3ʹʹ (antisense); human MitoPLD, 5ʹ-CTCTGCCTGTTCGCCTTCT-3ʹ (sense) and 5ʹ-CATTCTCCCTGTTGTTCTGG-3ʹ (antisense).
Tissue dot blot. Dot blotting was carried out using a human multiple tissue expression array (Clontech) as per manufacturer's instructions.
CLS complementation assay. Saccharomyces cerevisiae cls (YDL142C) and human
MitoPLD genes were individually subcloned into pYES2 vectors (Invitrogen), and transformed separately into cls null yeast cells (MATα, cls, ura3, leu2, met) . Subsequently, transformed yeast cells were labelled with 10 μCi ml -1 3 H-palmitate, and CLS and MitoPLD protein expressions were induced by galactose for 14-16 h. Yeast cells were broken open with glass beads, and lipids were then extracted and analysed by thin layer chromatography, followed by autoradiography as described in the Supplementary Information, Methods. Positions of cardiolipin and phosphatidylglycerol spots were determined by standard lipids (Sigma) visualized by iodine staining.
In vitro cardiolipin PLD assay. Recombinant bacmids were prepared by transformation of DH10Bac Escherichia coli cells with the pFastBac (Invitrogen) containing wild-type and mutant MitoPLD cDNAs C-terminally tagged with 6×His. Recombinant baculoviruses were amplified and propagated using standard procedures. Monolayer cultures of exponentially growing Sf9 cells were infected with baculoviruses at a multiplicity of 10 and were cultured for 48 h at 27 °C. The proteins were purified by Ni-NTA agarose (Qiagen), eluted using imidazole (250 mM), dialyzed against PBS, and quantitated using Coomassie Plus protein assay reagent (Pierce, Rockford, IL).
NIH3T3 cells (4 × 10 7 ) were labelled with 2 μCi ml
H-palmitic acid (American Radiolabeled Chemicals, St Louis, MO) for 24 h, harvested and subjected to lipid extraction. The resulting lipids were separated by TLC, and silica corresponding to the retardation factor (Rf) value of a cardiolipin standard was scraped off of the TLC plate. Radiolabelled cardiolipin was extracted from the silica, mixed with bovine heart lipid extracts (150 μg; Avanti Polar Lipids, Alabaster, AL), dried down and resuspended in HEPES buffer (10 mM at pH 7.4) using sonication. The assay was performed at 37 °C for 30 min with cardiolipin (100,000 dpm), MitoPLD (500 ng) and assay buffer (50 mM HEPES at pH 7.5, 80 mM KCl, 1 mM DTT, 3 mM MgCl 2 and 2 mM CaCl 2 ) in a total volume of 100 μl. The reaction was stopped with CH 3 OH:CHCl 3 :0.1 M HCl (10:5:4, v/v) and the lipids recovered by acid organic extraction (half-volumes each of CHCl 3 , 0.1 M HCl and 0.5 M NaCl). The organic fraction was dried down, dissolved in chloroform, and separated on a 10× 10-cm silica gel 60 HPTLC plate (EMD Chemicals, Gibbstown, NJ) using chloroform:methanol:water:ammonium hydroxide (120:75:6:2, v/v) as the solvent. The position of phosphatidic acid and cardiolipin on the analysis plate was determined by matching the migration distances to cold standards run in parallel and was visualized using iodine staining. and cleavage site predicted for human MitoPLD protein by the MITOPROT program (http://ihg.gsf.de/ihg/mitoprot.html), which estimated a 78% probability that MitoPLD would localize to mitochondria. MLSs are generally amphipathic and positively charged; the MitoPLD MLS is amphipathic and contains 9 positively-charged residues and 1 negative charged residue. However, these guidelines refer primarily to imported proteins, which we show later does not appear to take place for MitoPLD, so the computer prediction is of less significance in this instance. Amino acid residues 5-27 (numbering according to the human sequence) were alternately predicted to function as a transmembrane helix by the TMHMM program (http://www.cbs.dtu. dk/services/TMHMM/). Other regions of interest are underlined. Red indicates highly conserved amino acid residues. Blue represents less highly conserved residues. TM, transmembrane; CLS, cardiolipin synthase. The RGV motif has not previously been described and its function is currently unknown; it could play a role in protein:protein or protein:lipid interactions since it lies at the back of the enzyme with respect to the active site (see Fig. 1h ). The human MitoPLD gene localizes to human chromosome 17p11.2.
Figure S2
MitoPLD topology as determined by surface digestion using Trypsin, and lack of protein:protein interaction of MitoPLD with Mfn or effects of MitoPLD deficiency on Mfn expression. (a) Topology. Mitochondria purified from cells expressing FLAG-tagged wt or H156N MitoPLD were exposed to trypsin. Hsp60 (a mitochondrial matrix protein), VDAC (an integral outer membrane protein), and TOM20 (which projects from the outer membrane) were visualized using commercial antisera. (b) Co-IP. NIH3T3 cells were transiently co-transfected with plasmids for FLAG-and EGFPtagged MitoPLD or control plasmids as indicated (hNuc2 is another presently uncharacterized HKD-containing gene that exhibits sequence similarity to bacterial Nuc but does not localize to mitochondria, unpublished data; Mito-EGFP is EGFP fused to the MLS of subunit VIII of human cytochrome C oxidase). Twenty-four hours post-transfection, the cells were lysed using 0.5% NP-40 in PBS, sonicated, and centrifuged at 13K x g for 5 min at 4 o C. The resulting supernatants were incubated with anti-EGFP (Abcam) or anti-FLAG (Sigma) antibodies in the presence of protein G-agarose (Sigma). The agarose was washed in lysis buffer, and the bound proteins were eluted using SDS loading buffer, subjected to 12% SDS-PAGE, transferred to nitrocellulose membranes and detected with an Odyssey infrared imaging system using the antibodies indicated. IP indicates antibody used for immunoprecipitation; IB indicates antibody used for western blot immunodetection. Asterisk indicates non-specific band detected by anti-EGFP antibody. Examination of the Input lanes indicates that all of the proteins were expressed at approximately equivalent levels. When FLAG-tagged MitoPLD was co-expressed with EGFP-tagged MitoPLD and immunoprecipated using either anti-FLAG or anti-EGFP antibody, the partner protein (EGFP-tagged MitoPLD or FLAG-tagged MitoPLD, respectively) was readily detected by western blot analysis. However, the partner proteins were not co-immunoprecipitated by Mito-EGFP or by hNuc2-FLAG, demonstrating specificity of the immunoprecipitation and detection reactions.(c) Mfn1 and 2 levels of expression are not altered in MitoPLD RNAi-targeted cells. Western blot analysis of parental cells, cells expressing tagged Mfn proteins, and control or MitoPLD RNAi-targeted cells were subjected to Western blot analysis using polyclonal antisera directed against Mfn1 and Mfn 2 with previously described protocols (4, 10) . Left, Mfn1 analysis: In Lane 1, the parental NIH3T3 cells, many immunoreacting bands are observed. In Lane 2, a larger band is observed, indicating transiently-expressed EGFP-Mfn1 and demonstrating that the antibody does recognize Mfn1. Breakdown products, including one at approximately 80 kDa, which is close to the predicted size of Mfn1 (84 kDa), are also observed. In Lane 3, the antibody fails to recognize transiently EGFP-tagged Mfn2, demonstrating that it is isoform-specific. In lane 4, examination of mouse embryonic fibroblasts lacking Mfn1 indicates the disappearance of multiple immunoreactive bands -a major one migrating at approximately 80 kDa, a doublet almost as intense at approximately 110 kDa, and possibly several higher molecular weight bands (probably indicating incomplete denaturation and /or reassociation with other hydrophobic proteins during electrophoresis). Regardless, no difference in the level of Mfn1 is observed for the major band at 80 kDa between HeLa cells targeted using RNAi directed against Luciferase (Lane 5) versus ones targeted against MitoPLD (Lane 6). Similarly, no difference in the level of Mfn2 is observed between for the Luc (lane 7) or MitoPLD (Lane 8) RNAi targeted cell lines. Note -lanes 1-6 all derive from the same experiment and autorad, however, several non-relevant intervening lanes were excised from the figure between lanes 4 and 5. Lanes 7-8 derive from a separate western blot experiment.
